Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis

Transplantation

Volumn 90, Issue 10, 2010, Pages 1091-1098

  Kuo, Hung Tien ^a,b   Ye, Xiaoyi ^a   Sampaio, Marcelo Santos ^a,c   Reddy, Pavani ^a   Bunnapradist, Suphamai ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

Author keywords

Cytomegalovirus; Kidney transplant; Serostatus pairing; Transplant outcomes

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CYCLOSPORIN; CYTOKINE RECEPTOR ANTAGONIST; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CADAVER DONOR; CHEMOPROPHYLAXIS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK REDUCTION; SURGICAL MORTALITY; TREATMENT OUTCOME;

ACYCLOVIR; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DATABASES, FACTUAL; FEMALE; GANCICLOVIR; GRAFT REJECTION; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE DONORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 78650268283     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181f7c053     Document Type: Article

References (20)

1. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001;12:848.
2. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005;16:1758.
3. Schnitzler MA, Lowell JA, Hardinger KL, et al. The association of cyto-megalovirus sero-pairing with outcomes and costs following cadaveric renal transplantation prior tothe introductionof oral ganciclovir CMV prophylaxis. Am J Transplant 2003;3:445.
4. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovi-rus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002;2:850.
5. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalo-virus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004;66:329.
6. Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomeg-alovirus infection and disease in renal transplant recipients. Transplantation 2006;82(2 suppl):S15.
7. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004;4:928.
8. Johnson RJ, Clatworthy MR, Birch R, et al. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients. Transplantation 2009;88:77.
9. Jassal SV, Roscoe JM, Zaltzman JS, et al. Clinical practice guidelines: Preventionof cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 1998;9:1697.
10. Reischig T, Jindra P, Svecova M, et al. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol 2006;36:146.
11. McLaughlin K, Wu C, Fick G, et al. Cytomegalovirus seromismatching increases the risk of acute renal allograft rejection. Transplantation 2002;74:813.
12. Pescovitz MD. Valganciclovir: Recent progress. Am J Transplant 2010;10:1.
13. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganci-clovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611.
14. Kalil AC, Freifeld AG, Lyden ER, et al. Valganciclovir for cytomegalo-virus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy. PLoS One 2009;4: e5512.
15. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cyto-megalovirus disease and related outcomes with valganciclovir: A systematic review. Am J Transplant 2008;8:2111.
16. Doyle AM, Warburton KM, Goral S, et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared toa12-week course. T. Transplantation 2006;81:1106.
17. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010;10:1228.
18. Mourad G, Garrigue V, Squifflet JP, et al. Induction versus noninduc-tion in renal transplant recipients with tacrolimus-based immunosup-pression. Transplantation 2001;72:1050.
19. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomised controlled trials. Lancet 2005;365:2105.
20. Whitley RJ, Gnann JW Jr. Acyclovir: A decade later. N Engl J Med 1992;327:782.